iwCLL 2019 | The mechanism of ibrutinib in CLL treatment

Francesco Forconi

Francesco Forconi, MD, PhD, University of Southampton, Southampton, UK, discusses the mechnisms by which ibrutinib works on B-cell receptor (BCR) signalling in chronic lymphocytic leukemia (CLL) treatment and how we might find alternative targets. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video